Autonomic dysfunction is a common and clinically meaningful feature of neurodegenerative diseases, including Parkinson’s disease and multiple system atrophy, and its evaluation plays an important role in differential diagnosis, phenotyping, assessment of disease severity, and prediction of prognosis1,2. Among autonomic manifestations, cardiovascular involvement is of particular clinical importance, with orthostatic hypotension (OH) being a key feature. In patients with neurodegenerative diseases, OH is associated with an increased risk of falls, syncope, and cognitive decline, underscoring the need for accurate and reproducible assessment3,4.
The head‑up tilt test (HUT) is widely used as a standard method for evaluating OH. Based on the temporal profile following postural change, OH is subclassified into initial (immediate) OH, classic OH, and delayed OH. In addition to blood pressure responses, assessment of heart rate changes during HUT allows application of this test to the diagnosis of postural orthostatic tachycardia syndrome (POTS) (Table 1)5,6. Unlike neurogenic orthostatic hypotension, which is commonly associated with neurodegenerative diseases, POTS typically affects younger individuals and is rarely linked to these disorders. Furthermore, analysis of the relationship between heart rate responses and the magnitude of blood pressure reduction provides clinically useful information for distinguishing neurogenic OH from non‑neurogenic OH5,7.
Other methods for evaluating cardiovascular autonomic function include the active standing test (Schellong test), the Valsalva maneuver, and the deep breathing test. The active standing test is particularly useful for assessing orthostatic blood pressure responses, including initial OH, whereas the Valsalva maneuver and deep breathing test primarily assess autonomic function and are more dependent on the subject’s active cooperation and testing conditions.
In contrast, HUT provides a passive and standardized orthostatic challenge, allowing strict control of testing conditions and highly reproducible assessment of cardiovascular autonomic responses. Although HUT is conceptually simple—assessing blood pressure responses during passive transition from the supine to the upright position—several methodological factors must be carefully considered to ensure reliable and reproducible results. These include environmental influences on autonomic function and appropriate interpretation of continuously fluctuating blood pressure signals. Such considerations are particularly important in patients with neurodegenerative diseases, who are often older and susceptible to comorbid conditions and medication-related effects.
In this video article, we present a standardized, practical HUT protocol for evaluating cardiovascular autonomic dysfunction in neurodegenerative diseases. We provide detailed guidance on test timing, control of the testing environment, pre‑test dietary considerations, and continuous noninvasive blood pressure monitoring. Key procedural parameters, including tilt table angle, tilt‑up speed, and the duration of blood pressure monitoring, are described in detail, along with essential precautions to ensure patient safety during the examination.
The active standing test is widely used to assess orthostatic blood pressure responses and is particularly useful for evaluating initial OH5. When a tilt table is not available, it may also serve as an alternative method for assessing OH8,9,10. Although the standing test lacks a strictly standardized protocol, it is closely related to HUT and is widely used in clinical practice. Therefore, its general procedure and interpretation are briefly demonstrated in the latter part of this video article.
Through these demonstrations, we aim to promote adoption of a standardized, reproducible, and clinically applicable HUT protocol that can be implemented consistently across clinical and research settings. Such standardization is expected to improve comparability between studies and to enhance the assessment of cardiovascular autonomic dysfunction in patients with neurodegenerative diseases.